FindTrial
Sign In

Application of the autologous CAR T cells (Tarcidomgen Kimleucel) in the treatment of refractory and relapsed CD19+ B cell neoplasms

Status
Not yet recruiting
Phases
Phase 1
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-520653-37-00
Acronym
CARLA
Enrollment
6
Registered
2025-01-30
Start date
Unknown
Completion date
Unknown
Last updated
2025-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Application of the autologous CAR T cells (Tarcidomgen Kimleucel) in the treatment of refractory and relapsed CD19+ B cell neoplasms

Interventions

None listed

Sponsors

Famicordtx S.A., Polski Bank Komorek Macierzystych Sp. z o.o.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Countries

Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026